GSK Announces FDA Approval of Altabax (Retapamulin Ointment), 1%
First New Class of Topical Antibacterials in Nearly Two Decades
PHILADELPHIA, April 12, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.
Altabax represents the first new class of prescription topical antibacterials to be approved by the FDA in nearly two decades. Altabax is indicated for use twice daily for a five-day period in patients nine months of age and older. Other prescription topical antibacterials are used as much as three times daily for up to 12 days.
"The introduction of Altabax comes at a time when antibiotic resistance is at an increasingly high level," said Stan Block, MD, President, Kentucky Pediatric and Adult Research Inc. "Altabax provides clinicians with a convenient new means to effectively fight the bacteria that cause impetigo
Posted: April 2007
Related articles
- GSK Receives Approvable Letter for Topical Antibiotic, Altabax (retapamulin ointment), 1% - December 22, 2006
- GlaxoSmithKline's Topical Antibacterial Retapamulin Accepted for Review by The U.S. Food and Drug Administration - February 14, 2006
Altabax (retapamulin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
